Americans now say they approve of free trade by 64%-27%, a margin of better than two to one. That's up from 57%-37% early in Trump's presidency, and 51%-41% near the end of...Politicsread more
Trump said Cook made a "good case" that it would be difficult for Apple to pay tariffs, when Samsung does not face the same hurdle because much of its manufacturing is in...Technologyread more
Kudlow pointed to strong retail sales and low unemployment as signs that the U.S. economy remained strong.Marketsread more
The yield on the benchmark 10-year Treasury note briefly fell below the 2-year rate on Wednesday, a phenomenon in the bond market known as yield curve inversion, which is...Marketsread more
The MacBook Pro recall and its subsequent ban from flights underscores the increasing brand risk from problems with lithium-ion batteries.Technologyread more
Despite aggressive strides, Waymo needs one thing before their self-driving cars become a seriously useful transportation system: people. We talked to the ones closest to it.Technologyread more
Experts say the timing of Amazon executives' contributions to Rep. David Cicilline likely reflect the company's heightened urgency over growing regulatory scrutiny.Technologyread more
CNBC combed through Wall Street research to see which stocks are still a buy after their earnings reports.Marketsread more
Coinbase security chief Philip Martin explains, "Possession of a key is possession of your currency. What that means is that you can't revoke a cryptocurrency key, if that key...Technologyread more
Fraud investigator Harry Markopolos' accusations extended beyond GE's management to actuaries, auditors and analysts who he claims overlooked billions in liabilities.Marketsread more
The Supreme Court could strike down the constitutionality of the Consumer Financial Protection Bureau, an agency Elizabeth Warren has likened to her child and which Justice...2020 Electionsread more
British artificial intelligence start-up BenevolentAI has bagged $115 million from investors, lifting its pre-money valuation to $2 billion.
The London-based firm, which is focused on the pharmaceutical industry, said the latest round of funding will help it scale drug development and its AI platform.
The company currently has more than 20 drug programs. It said it will use the raised capital to expand into other areas of the market like advanced materials, agriculture and energy storage.
Its AI technology is used to decipher the molecular process of disease and match drug treatments to the most applicable patients.
BenevolentAI created a bioscience machine "brain" that uses algorithms and data to locate the cause of diseases and generate insights into them that humans otherwise couldn't. Its platform is being used to develop treatments for incurable diseases like motor neurone disease, Parkinson's disease, glioblastoma and sarcopenia.
Some worry that the U.K.'s decision to leave the European Union could hamper innovation and scientific research. The EU's single market lets firms move goods, capital, services and labor freely and the soon-to-be 27-member bloc offers funding schemes for science and research programs.
But Ken Mulvany, founder and chairman of BenevolentAI, said that Britain remained an attractive hub for science.
"There's a tremendous heritage of scientific innovation here in the U.K.," he told CNBC's "Street Signs Europe." "It certainly has been batting well above its weight in that respect."
The British government launched an initiative last year to boost skills and education and grow the country's AI industry. Mulvany said the government's strategy on AI was positive for the sector.
"The U.K. is one of the leading sectors for AI innovation," Mulvany said. "You see it in Toronto, you see it in Stanford and we're seeing it in the knowledge quarter here in London."